FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.222,87 -581,93 (-0,97%)
Procaps Group S.A. (PROC)
| Chiusura precedente | 2,6000 |
| Aperto | 2,6500 |
| Denaro | 2,6100 x 100 |
| Lettera | 2,9700 x 100 |
| Min-Max giorno | 2,7271 - 2,7271 |
| Intervallo di 52 settimane | 1,9500 - 4,9500 |
| Volume | |
| Media Volume | 12.280 |
| Capitalizzazione | 307,682M |
| Beta (5 anni mensile) | 0,13 |
| Rapporto PE (ttm) | 5,35 |
| EPS (ttm) | 0,5100 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 4,75 |
GlobeNewswireProcaps Group Reports First Quarter 2023 Results
Constant Currency Net Revenues Increased 10% Quarter-over-Quarter in 1Q23, and 22% increase in Adjusted EBITDA, With Strong Demand of RX and Softgel Portfolios, Offset by Clinical Specialty Covid PortfolioMIAMI and BARRANQUILLA, Colombia, June 05, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps”), a leading integrated international healthcare and pharmaceutical services company, today announced its 1Q23 financial results. “We are executing on our value creation initiatives
- GlobeNewswire
Financial Results and Business Update Conference Call to be Held May 2023 in Conjunction with 20-F Filing
MIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today that it will file its Form 20-F and publish its Full Year 2022 Earnings Release before May 15th. The delay in filing the 2022 Form 20-F is because additional time is necessary to prepare and complete the internal review of the Company’s financial statements for the year ended Dece
